益肾健脾汤对脂代谢异常多囊卵巢综合征患者再次冻融胚胎移植结局的影响

Abstract
Figure/Table
References (0)
Related Citation (8)

Download: PDF (1366 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the effectiveness of YiShenJianPi decoction on blood lipid in women with polycystic ovary syndrome, and to investigate the impact on the outcome of FET cycles. Methods: A prospective study was performed in 227 women with PCOS and dyslipidemia who underwent the failure of first FET cycle. Patients in group A (n=55) received lifestyle modification programs. Patients in group B (n=85) received lifestyle modification and metformin. Patients in group C (n=87) received lifestyle modification and YiShenJianPi decoction. BMI, WHR, T, TC, TG, LDL-C, HDL-C were compared before and after treatment in all patients. Clinical outcome of re-FET was valued, including embryo implantation rate,clinical pregnancy rate, early abortion rate and live birth delivery rate. Results: T, TC, and TG of 3 groups, LDL-C and HDL-C of group B, C, WHR of group C, were all significantly improved after treatment (P<0.05), and meanwhile compared to group A, T, TC, LDL-C declined obviously and HDL-C increased remarkably in group B, C (P<0.05). The embryo implantation rate of group C (43.98%) was significantly higher than that of group A (31.68%) and B (35.06%) (P<0.05). No significant differences were detected in the clinical pregnancy rate early abortion rate and live birth delivery rate among 3 groups (P>0.05). Conclusion: The three strategies mentioned above could obviously alter dyslipidemia and help patients produce ideal pregnancy outcome, with YiShenJianPi decoction in particular, as it could remarkably increase the embryo implantation rate of FET.

Key words： polycystic ovary syndrome dyslipidemia frozen embryo transfer

Received: 25 January 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TENG Yili
	YU Rong
	XU Zhihui
	PAN Jiexue
	YANG Haiyan

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I6/418

[1] GOODARZI M O, AZZIZ R. Diagnosis, epidemiology and genetics of the polycystic ovary syndrome[J]. Best Pract Res Clin Endocrinol Metab, 2006, 209(2): 193-205.
[2] 中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6.
[3] MORON L,TEEDE H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome[J]. Hum Reprod Update,2009,15(4):477-488.
[4] CHANG R J. The reproductive phenotype in polycystic ovary syndrome[J]. Nat Clin Pract Endocrinol Metab, 2007, 3(10): 688-695.
[5] KIRANMAYEE D, KAVYA K, HIMABINDU Y, et al. Correlations between anthropometry and lipid profile in women with PCOS[J]. J Hum Reprod Sci, 2017, 10(3): 167-172.
[6] 莫馥华. 正常BMI腹型肥胖及血脂异常对IVF/ICSI妊娠结局影响的研究[D]. 南宁: 广西医科大学, 2016.
[7] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(1): 19-25.
[8] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-953.
[9] 郑筱萸.中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 142.
[10] FAUSER B C, TARLATZIS B C, REBAR R W, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group[J]. Fertil Steril, 2012, 97(1): 28-38.
[11] 谷伟军. 多囊卵巢综合征的诊断和治疗国内外指南解读[J]. 药品评价, 2016, 21(3): 5-8.
[12] DIAMANTI-KANDARAKIS E, DUNAIF A. Insulin resistance and the polycystic ovary syndrome revisited:an update on mechanisms and implications[J]. Endocr Rev, 2012, 33(6): 981-1030.
[13] 陈志英, 陈洁. 妊娠期糖尿病并发子痫前期的危险因素及妊娠结局分析[J]. 中国妇幼保健, 2017, 32(12): 2616-2618.
[14] CONWAY G, DEWAILLY D, DIAMANTI-KANDARAKIS E, et al. The polycystic ovary syndrome:a position statement from the European Society of Endocrinology[J]. Eur J Endocrinol, 2014, 171(4): 1-29.
[15] 黄晓燕, 吕红, 吴春香, 等. 多囊卵巢综合征患者的体质量指数和脂代谢水平对促性腺激素释放激素拮抗剂方案妊娠结局的影响[J]. 中华生殖与避孕杂志, 2018, 38(12): 969-975.
[16] BELLVER D J, METO M A, BOSCH E, et al. Obesity and poor reproductive outcome: the potential role of the endo-metrium[J]. Fertil Steril, 2007, 88(2): 446-451.
[17] PALOMBA S, FALBO A, CHIOSSI G, et al. Lipid profile in nonobese pregnant women with polycystic ovary syndrome: a prospective controlled clinical study[J]. Steroids, 2014, 88(6): 36-43.
[18] VIVIAN R, SRIVIDYA S, SESH K S. Effect of body mass index on IVF treatment outcome:an updated systematic review and meta-analysis[J]. Reprod Biomed Online, 2011, 23(4): 421-439.
[19] LEGRO R S, DODSON W C, KRIS-ETHERTON P M, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 2015, 100(11): 4048-4058.
[20] 薛艳军, 谢华, 孙美灵, 等. PCOS合并胰岛素抵抗的血脂代谢异常特点分析[J]. 中国现代医学杂志, 2014, 24(25): 94-98.
[21] MCGOWAN B M,BLOOM S R. Peptide YY and appetite control[J]. Curr Opin Pharmacol, 2009, 4(6): 583-588.
[22] 张凤. 多囊卵巢综合征脂类代谢异常及其治疗[J]. 国际生殖健康/计划生育杂志, 2011, 30(2): 126-128.
[23] NADERPOOR N, SHORAKAE S, COURTEN B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis[J]. Hum Reprod Update, 2015, 21(5): 560-74.
[24] 刘东, 郭娇, 朴胜华. 血脂异常中医药临床评价与分析[J]. 中国民族民间医药, 2013, 13(2): 28-29.